ProPublica Investigation Warns FDA Peptide Reversal Could Open Market to Unsafe Drugs

As the FDA prepares to reclassify approximately 14 previously restricted peptides back to Category 1 status — a move championed by HHS Secretary Robert F. Kennedy Jr. — a ProPublica investigation is raising pointed questions about whether the regulatory framework can keep patients safe.

The core tension

The investigation highlights a fundamental contradiction in the current peptide landscape. On one side, FDA-approved peptide drugs like semaglutide, a GLP-1 receptor agonist, and tirzepatide, a dual GIP/GLP-1 receptor agonist, have undergone rigorous clinical trials and post-marketing surveillance. On the other, peptides like BPC-157, a synthetic peptide derived from a protein found in gastric juice, are being returned to compounding pharmacy access based primarily on preclinical research — animal studies and in-vitro data rather than the large-scale human trials required for FDA drug approval.

ProPublica's reporting notes that while these peptides have generated enthusiastic communities of users reporting benefits for tissue repair, inflammation, and cognitive function, the evidence base remains thin by pharmaceutical standards. Most human data comes from case reports and small observational studies, not randomized controlled trials.

Compounding quality under scrutiny

The investigation also examines the quality control gap between FDA-approved manufacturers and compounding pharmacies. Section 503A pharmacies, which compound individual prescriptions, are primarily regulated by state boards of pharmacy rather than the FDA. Section 503B outsourcing facilities face more federal oversight but still operate under a lighter framework than traditional drug manufacturers.

Recent enforcement actions — including the shutdown of gray-market vendor Peptide Sciences — exposed quality failures that underscore these concerns. Independent testing of products from various vendors revealed inconsistencies in purity, potency, and sterility.

The policy debate

The ProPublica piece arrives at a pivotal moment. The wellness industry and a growing cohort of integrative medicine practitioners argue that restricting access to peptides with decades of research use harms patients. Critics counter that popularity is not evidence, and that the FDA's original Category 2 restrictions reflected legitimate safety concerns.

What both sides may agree on: the current regulatory framework — designed for traditional small-molecule drugs — was never built to handle the nuances of peptide compounding. Whether the FDA's reclassification comes with strengthened quality requirements for compounding pharmacies may ultimately determine whether expanded access translates to better patient outcomes or more adverse events.